NCT00016107View on ClinicalTrials.gov

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

February 28, 2007

Conditions
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

estramustine phosphate sodium

Given orally

DRUG

docetaxel

Given IV

BIOLOGICAL

bevacizumab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00016107 - Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter